DJO Incorporated Announces Financial Results for Third Quarter 2007

DJO Incorporated (NYSE:DJO), a global provider of products and services that promote musculoskeletal and vascular health, today announced financial results for the third quarter of 2007, ended September 29, 2007. Third Quarter Results Net revenues for the third quarter of 2007 were $119.8 million, reflecting an increase of 5.8 percent, compared with net revenues of $113.2 million in the third quarter of 2006. The third quarter of 2006 included a revenue benefit of approximately $1.9 million due to a change in shipping terms for certain Aircast products and the clearing of product backorders that were outstanding at the end of the second quarter of 2006 due to the impact of integration activities taking place at that time. Excluding this 2006 revenue benefit, third quarter 2007 revenues increased approximately 7.6 percent from the third quarter of 2006. The third quarters of 2007 and 2006 each included 63 shipping days. Non-GAAP net income for the third quarter of 2007 was $8.2 million, or $0.34 per share, reflecting an increase of 23.9 percent, compared to non-GAAP net income of $6.6 million, or $0.28 per share, for the third quarter of 2006. Non-GAAP net income results for the third quarter of 2007 exclude transaction costs related to the Company’s planned merger with ReAble Therapeutics ($1.5 million, net of tax). Non-GAAP results in the third quarter of 2006 excluded the impact of certain charges and expenses related to acquisitions ($1.4 million, net of tax), and the Company’s move into its new corporate headquarters ($0.8 million, net of tax). Non-GAAP net income for the third quarters of 2007 and 2006 has been reduced by the after-tax effect of non-cash stock-based compensation expense of $2.3 million, or $0.09 per share, and $2.3 million, or $0.10 per share, respectively. GAAP net income for the third quarters of 2007 and 2006 was $6.7 million, or $0.28 per share, and $4.4 million, or $0.18 per share, respectively. The Company defines adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, stock-based compensation expense and certain charges and expenses not deemed to be reflective of the ongoing operations of the Company, as discussed above. Adjusted EBITDA for the third quarter of 2007 was $31.8 million, or 26.5 percent of net revenues, reflecting an increase of 11.1 percent, compared to adjusted EBITDA of $28.6 million, or 25.3 percent of net revenues, for the third quarter of 2006. Nine Month Results Net revenues for the first nine months of 2007 were $354.9 million, reflecting an increase of 17.4 percent, compared with net revenues of $302.3 million for the first nine months of 2006. Revenues for the first nine months of 2007 included full contribution from the Company’s Aircast acquisition, which closed April 7, 2006. On a pro forma basis, as if the Aircast acquisition had closed on January 1, 2006, revenue for the first nine months of 2007 reflected growth of approximately 8.5 percent over the corresponding prior year period. The first nine months of 2007 and 2006 each included 191 shipping days. Non-GAAP net income for the first nine months of 2007 was $22.3 million, or $0.93 per share, compared with non-GAAP net income of $18.2 million, or $0.78 per share, for the first nine months of 2006. Non-GAAP net income for the first nine months of 2007 and 2006 was reduced by the after-tax effect of stock-based compensation expense of $5.5 million, or $0.23 per share, and $5.3 million, or $0.23 per share, respectively. For the first nine months of 2007, in addition to the merger-related adjustments noted above for the third quarter of 2007, non-GAAP net income excludes the impact of certain adjustments that the Company does not believe are reflective of its ongoing operations, including an adjustment to write down raw material inventories ($0.5 million, net of tax), an increase in the Company’s estimates of bad debt reserves required for certain aged accounts receivable from third-party payors and patients ($2.6 million, net of tax), certain costs and expenses related to the integration of the acquired Aircast business ($1.2 million, net of tax) and costs related to the settlement of outstanding litigation ($0.3 million, net of tax). For the first nine months of 2006, non-GAAP net income excluded purchase accounting adjustments to write up acquired company inventories (Axmed and Aircast) to fair value ($0.9 million, net of tax), certain costs and expenses related to the integration of acquired businesses ($4.4 million, net of tax), certain costs and expenses related to the Company’s move into its new corporate headquarters ($0.8 million, net of tax), costs related to an arbitration that concluded in the second quarter of 2006 ($0.4 million, net of tax) and the write-off of previously deferred expenses related to a discontinued acquisition ($0.1 million, net of tax). GAAP net income for the first nine months of 2007 was $16.1 million, or $0.67 per share, compared with GAAP net income of $11.6 million, or $0.50 per share, for the first nine months of 2006. Adjusted EBITDA for the first nine months of 2007 was $87.0 million, or 24.5 percent of net revenues, reflecting an increase of 22.2 percent, compared to adjusted EBITDA of $71.2 million, or 23.5 percent of net revenues for the first nine months of 2006. "We had a busy third quarter at DJO. Our core business continues to perform well with solid top-line growth and improved operating metrics highlighting the quarter. We also completed certain milestones required prior to closing the planned merger with ReAble Therapeutics,” said Les Cross, president and CEO. "Net revenues for the third quarter reached $119.8 million, growing about 6% over the third quarter of 2006. In the third quarter of 2006, DJO realized a sizable revenue benefit of approximately $1.9 million within our Domestic Rehabilitation and International business segments, the result of a change in Aircast shipping terms and the clearing of product backorders from the second quarter of 2006. Excluding this revenue benefit last year, revenue growth across the Company was approximately 8% in the third quarter of 2007. "Our Regeneration segment had a strong quarter with total segment revenue growing over 21% compared to the third quarter of 2006, and with our SpinaLogic® product line growing more than 37% over the prior year period. The share gains we continue to realize in the spine stimulation market are the result of our expanding distribution strategy in the U.S. that includes both direct and independent representatives. "Our International segment also delivered strong revenue growth of approximately 13%, aided by our strategy to broaden our product lines in an expanding geographical footprint of direct distribution and also by favorable changes in foreign exchange rates. "We were pleased to see solid sequential improvement in our gross profit and operating margins from the second quarter of this year as we made further progress with our cost initiatives. On a non-GAAP basis, our gross profit margin improved sequentially from the second quarter by 120 basis points, to 62.0% of revenues. Similarly, on a non-GAAP basis, our operating margin improved by 140 basis points, to 17.4% of revenues. "Another highlight of the third quarter was our strong cash flow. We generated approximately $24.1 million in cash from operations, before the impact of the merger related costs incurred during the quarter. We used this cash and $3.4 million received from the sale of the vacated Aircast New Jersey manufacturing facility to repay $25.5 million of debt during the third quarter. Our cash balances at the end of the quarter remained strong at approximately $12 million. "We continue to be very excited about the merger of ReAble and DJO, which brings together two leaders in orthopedics and rehabilitation and creates a formidable new organization with complementary product lines and distribution synergies that should provide market opportunities worldwide for both companies’ product lines. We are well on our way to closing the transaction. We have completed all necessary approvals with the exception of the approval of our stockholders. The special meeting of our stockholders is scheduled for November 6, 2007. We continue to look forward to a fourth quarter closing.” Recent Business Highlights: DJO Incorporated entered into a merger agreement with ReAble Therapeutics on July 15, 2007. The merger agreement provides for DJO stockholders to receive $50.25 per share in cash in a transaction valued at approximately $1.6 billion. In August 2007, DJO received accreditation status by the Accreditation Commission for Health Care, Inc. (ACHC), a private, not-for-profit corporation developed by home care and community-based providers to help companies improve their business operations and the quality of patient care. In August 2007, DJO received FDA market approval for enhanced patient features for its line of OL1000 and SpinaLogic bone growth stimulation products. In September 2007, DJO was named to the Deloitte & Touche "Technology Fast 50” list of San Diego’s fastest growing companies for the fifth year in a row. About DJO Incorporated DJO Incorporated is a global provider of solutions for musculoskeletal and vascular health, specializing in rehabilitation and regeneration products for the non-operative orthopedic, spine and vascular markets. Marketed under the Aircast®, DonJoy® and ProCare® brands, the Company’s broad range of over 750 rehabilitation products, including rigid knee braces, soft goods and cold therapy products, are used in the prevention of injury, in the treatment of chronic conditions and for recovery after surgery or injury. The Company’s regeneration products consist of bone growth stimulation devices that are used to treat nonunion fractures and as an adjunct therapy after spinal fusion surgery. The Company’s vascular systems products help prevent deep vein thrombosis and pulmonary embolism that can occur after orthopedic and other surgeries. Together, these products provide solutions throughout the patient’s continuum of care. The Company sells its products in the United States and in more than 75 other countries through networks of agents, distributors and its own direct sales force. Customers include orthopedic, podiatric and spine surgeons, orthotic and prosthetic centers, third-party distributors, hospitals, surgery centers, physical therapists, athletic trainers, other healthcare professionals and individual and team athletes. For additional information on the Company, please visit www.djortho.com. Safe Harbor Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements relate to, among other things, the Company’s pending merger with ReAble Therapeutics, Inc. The words "believe,” "should,” "expect,” "intend,” "estimate” and "anticipate,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based on the Company’s current expectations and are subject to a number of risks, uncertainties and assumptions, many of which are beyond the Company’s ability to control or predict. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Some of the important factors that could adversely impact the pending merger with ReAble Therapeutics, Inc. or the Company’s results include disruption to the Company’s current plans and operations and potential difficulties in employee retention as a result of the merger; the occurrence of any event, change or other circumstance that could give rise to a termination of the merger agreement announced on July 16, 2007; the outcome of the pending legal proceedings that were instituted against our board of directors, DJO, ReAble and The Blackstone Group, ReAble’s parent company, following the announcement of the merger agreement; the inability to complete the merger due to the failure to obtain stockholder approval or the failure to satisfy other conditions to the merger; and the failure to obtain the necessary financing arrangements set forth in the commitment letters received in connection with the merger. Other risk factors are detailed in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2007, filed on August 3, 2007, with the Securities and Exchange Commission and may be updated by the Company’s other SEC filings, including the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 29, 2007. Additional Information About the Merger and Where to Find It In connection with the proposed merger referred to in the press release, DJO filed a definitive proxy statement with the SEC on October 9, 2007. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (AND ALL AMENDMENTS AND SUPPLEMENTS TO IT) AND OTHER MATERIALS THAT THE COMPANY MAY FILE WITH THE SEC IN THEIR ENTIRETY WHEN SUCH MATERIALS BECOME AVAILABLE, BECAUSE THE MATERIALS CONTAIN IMPORTANT INFORMATION ABOUT DJO AND THE PROPOSED MERGER. The final proxy statement was mailed to DJO’s stockholders. Stockholders are able to obtain free copies of the final proxy statement, as well as the Company’s other filings, without charge, at the SEC’s Web site (www.sec.gov) when they become available. Copies of the filings may also be obtained without charge from DJO by directing a request to: DJO Incorporated, 1430 Decision Street, Vista, CA, 92081, Attention: Mark Francois, Director of Investor Relations (Tel: 1-760-734-4766, Email: mark.francois@djortho.com). Participants in the Solicitation DJO and its directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from stockholders in respect of the proposed merger referred to in the press release. Information regarding DJO’s directors and executive officers is available in DJO’s 2006 Annual Report on Form 10-K, filed with the SEC on March 1, 2007 and DJO’s proxy statement for its 2007 annual meeting of stockholders, filed with the SEC on April 20, 2007. Additional information regarding the interests of such potential participants was included in the definitive proxy statement filed with the SEC on October 9, 2007 in connection with the Special Meeting of Stockholders. DJO Incorporated Unaudited Condensed Consolidated Statements of Income (In thousands, except per share data and number of operating days)     Three Months Ended   September 29, 2007   September 30, 2006   Net revenues $ 119,784 $ 113,205 Costs of goods sold (A),(B)   45,501     45,340   Gross profit 74,283 67,865 Operating expenses: Sales and marketing (A),(B) 35,621 33,398 General and administrative (A),(B) 11,336 13,075 Research and development (A),(B) 2,018 2,580 Amortization of acquired intangibles 4,503 4,510 Merger costs (A)   2,539     -   Total operating expenses   56,017     53,563   Income from operations 18,266 14,302 Interest expense and other, net   (4,999 )   (5,845 ) Income before income taxes 13,267 8,457 Provision for income taxes   (6,552 )   (4,098 ) Net income $ 6,715   $ 4,359   Net income per share: Basic $ 0.28   $ 0.19   Diluted $ 0.28   $ 0.18   Non-GAAP diluted net income per share (excluding the impact of certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company)       $     0.34       $     0.28   Weighted average shares outstanding used to calculate per share information: Basic   23,641     22,968   Diluted   24,251     23,598   Number of operating days 63 63   (A) Includes certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company, as follows (C): Gross profit $ - $ 2,442 Sales and marketing - 713 General and administrative 39 465 Research and development - 180 Merger costs   2,539     -   $ 2,578   $ 3,800   (B) Includes stock-based compensation expense, as follows (C): Gross profit $ 280 $ 308 Sales and marketing 1,373 1,222 General and administrative 1,191 1,015 Research and development   153     140   $ 2,997   $ 2,685     (C) See reconciliation of non-GAAP financial measures in table at end of press release. DJO Incorporated Unaudited Condensed Consolidated Statements of Income (In thousands, except per share data and number of operating days)     Nine Months Ended   September 29, 2007   September 30, 2006   Net revenues $ 354,869 $ 302,293 Costs of goods sold (A),(B)   140,841     119,961   Gross profit 214,028 182,332 Operating expenses: Sales and marketing (A),(B) 111,795 92,375 General and administrative (A),(B) 35,229 35,709 Research and development (A),(B) 6,185 6,745 Amortization of acquired intangibles 13,490 10,651 Merger costs (A)   2,539     -   Total operating expenses   169,238     145,480   Income from operations 44,790 36,852 Interest expense and other, net (A)   (15,705 )   (15,430 ) Income before income taxes 29,085 21,422 Provision for income taxes   (12,974 )   (9,790 ) Net income $ 16,111   $ 11,632   Net income per share: Basic $ 0.68   $ 0.51   Diluted $ 0.67   $ 0.50   Non-GAAP diluted net income per share (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company)         $       0.93         $       0.78   Weighted average shares outstanding used to calculate per share information: Basic   23,536     22,620   Diluted   24,082     23,330   Number of operating days 191 191   (A) Includes purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company, as follows (C): Gross profit $ 2,851 $ 5,565 Sales and marketing 4,612 1,160 General and administrative 340 1,622 Research and development - 187 Merger costs 2,539 - Interest expense and other, net   -     2,529   $ 10,342   $ 11,063   (B) Includes stock-based compensation expense, as follows (C): Gross profit $ 812 $ 688 Sales and marketing 3,727 3,175 General and administrative 3,089 2,545 Research and development   421     385   $ 8,049   $ 6,793     (C) See reconciliation of non-GAAP financial measures in table at end of press release. DJO Incorporated Unaudited Condensed Consolidated Balance Sheets (In thousands)         September 29,   December 31, Assets 2007 2006 Current assets: Cash and cash equivalents $ 11,956 $ 7,006 Accounts receivable, net 96,348 90,236 Inventories, net 43,422 47,214 Deferred tax asset, current portion 10,813 10,797 Prepaid expenses and other current assets   10,730   14,521 Total current assets 173,269 169,774 Property, plant and equipment, net 30,226 32,699 Goodwill, intangible assets and other assets 435,974 447,610 Deferred tax asset   10,288   18,251 Total assets $ 649,757 $ 668,334   Liabilities and stockholders’ equity Current liabilities: Accounts payable and other accrued liabilities $ 55,147 $ 66,331 Long-term debt, current portion   -   831 Total current liabilities 55,147 67,162 Long-term debt, less current portion 285,500 326,419 Accrued pension 271 201 Other long-term accrued liabilities 5,083 4,283 Total stockholders’ equity   303,756   270,269 Total liabilities and stockholders’ equity $ 649,757 $ 668,334 DJO Incorporated Unaudited Segment Information (In thousands, except number of operating days)     Three Months Ended Revenues per Day September 29,   September 30, September 29,   September 30, 2007 2006 2007 2006 Net revenues: Domestic Rehabilitation $ 74,935 $ 74,640 $ 1,189 $ 1,185 Regeneration 19,105 15,767 303 250 International   25,744     22,798     409   362 Consolidated net revenues   119,784     113,205   $ 1,901 $ 1,797   Gross profit: Domestic Rehabilitation 39,897 38,915 Regeneration 17,705 14,428 International   16,681     14,522   Consolidated gross profit (1)   74,283     67,865     Income from operations: Domestic Rehabilitation 12,155 11,033 Regeneration 6,111 3,139 International   6,261     4,530   Income from operations of reportable segments (2) 24,527 18,702 Expenses not allocated to segments (3)   (6,261 )   (4,400 ) Consolidated income from operations $ 18,266   $ 14,302   Number of operating days 63 63 (1) GAAP consolidated gross profit for the three months ended September 29, 2007 and September 30, 2006, includes:     Three Months Ended Three Months Ended September 29, 2007 September 30, 2006   Domestic Rehab   Regeneration   International Domestic Rehab   Regeneration   International   GAAP gross profit $ 39,897 $ 17,705 $ 16,681 $ 38,915 $ 14,428 $ 14,522 Certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company       -       -       -       2,343       32       67 Non-GAAP gross profit (excluding the impact of certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company)       $       39,897       $       17,705       $       16,681       $       41,258       $       14,460       $       14,589 (2) GAAP income from operations of reportable segments for the three months ended September 29, 2007 and September 30, 2006, includes:     Three Months Ended Three Months Ended September 29, 2007 September 30, 2006   Domestic Rehab   Regeneration   International Domestic Rehab   Regeneration   International   GAAP income from operations of reportable segments $ 12,155 $ 6,111 $ 6,261 $ 11,033 $ 3,139 $ 4,530 Certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company       -       -       -       3,164       150       399 Non-GAAP income from operations of reportable segments (excluding the impact of certain charges related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company)       $       12,155       $       6,111       $       6,261       $       14,197       $       3,289       $       4,929 (3) Expenses not allocated to segments for the three months ended September 29, 2007 and September 30, 2006 include costs not deemed to be reflective of the ongoing operations of the Company of $2.6 million and $0.1 million, respectively. DJO Incorporated Unaudited Segment Information (In thousands, except number of operating days)     Nine Months Ended Revenues per Day September 29,   September 30, September 29,   September 30, 2007   2006   2007 2006 Net revenues: Domestic Rehabilitation $ 219,842 $ 196,506 $ 1,151 $ 1,029 Regeneration 55,878 47,953 293 251 International   79,149     57,834     414   303 Consolidated net revenues   354,869     302,293   $ 1,858 $ 1,583   Gross profit: Domestic Rehabilitation 112,346 102,967 Regeneration 51,675 44,213 International   50,007     35,152   Consolidated gross profit (1)   214,028     182,332     Income from operations: Domestic Rehabilitation 24,821 30,310 Regeneration 16,538 10,560 International   18,396     8,851   Income from operations of reportable segments (2) 59,755 49,721 Expenses not allocated to segments (3)   (14,965 )   (12,869 ) Consolidated income from operations $ 44,790   $ 36,852   Number of operating days 191 191 (1) GAAP consolidated gross profit for the nine months ended September 29, 2007 and September 30, 2006, includes:     Nine Months Ended Nine Months Ended September 29, 2007 September 30, 2006   Domestic Rehab   Regeneration   International Domestic Rehab   Regeneration   International   GAAP gross profit $ 112,346 $ 51,675 $ 50,007 $ 102,967 $ 44,213 $ 35,152 Purchasing accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company         2,597         30         224         3,887         32         1,646 Non-GAAP gross profit (excluding the impact of purchasing accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company)         $         114,943         $         51,705         $         50,231         $         106,854         $         44,245         $         36,798 (2) GAAP income from operations of reportable segments for the nine months September 29, 2007 and September 30, 2006, includes:     Nine Months Ended Nine Months Ended September 29, 2007 September 30, 2006   Domestic Rehab   Regeneration   International Domestic Rehab   Regeneration   International   GAAP income from operations of reportable segments $ 24,821 $ 16,538 $ 18,396 $ 30,310 $ 10,560 $ 8,851 Purchasing accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company       6,287       703       224       5,097       150       2,469 Non-GAAP income from operations of reportable segments (excluding the impact of purchasing accounting adjustments to write up acquired inventories to fair value, certain charges related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company)           $ 31,108           $ 17,241           $ 18,620           $ 35,407           $ 10,710           $ 11,320 (3) Expenses not allocated to segments for the nine months ended September 29, 2007 and September 30, 2006 include costs not deemed to be reflective of the ongoing operations of the Company of $3.1 million and $0.8 million, respectively. DJO Incorporated Unaudited Reconciliation of Non-GAAP Financial Measures (In thousands, except per share data)   In managing its business, the Company makes use of certain non-GAAP financial measures in evaluating the Company's results of operations.   The events giving rise to certain purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to the Axmed and Aircast acquisitions, costs related to closing the ReAble acquisition and certain other costs and expenses are either not associated with the Company's normal operating business or not reflective of the ongoing business operations of the Company. Costs and expenses that the Company believes are not associated with or reflective of its ongoing business operations include costs related to litigation and arbitration settlements, the write-off of previously deferred expenses related to discontinued acquisitions, the write-off of unamortized deferred debt issuance costs related to the Company's former credit agreement, adjustments related to a complete count of raw material inventories subsequent to the Aircast integration and a charge to increase estimates of bad debts related to aged receivables due to the current impact of issues encountered in a prior year related to billing and collecting activities.   The Company also records significant non-cash stock-based compensation expense and non-cash amortization expense related to intangible assets acquired.   The Company believes disclosure of non-GAAP gross profit, non-GAAP income from operations, non-GAAP earnings and adjusted EBITDA has economic substance because the expenses excluded from these measures represent non-cash expenditures, or relate to transactions that are not associated with the Company's normal operating business.   The Company believes that presenting non-GAAP diluted earnings per share, excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions, certain other costs and expenses not deemed reflective of the ongoing business operations of the Company, and adjusted EBITDA are additional measures of performance that investors can use to compare operating results between reporting periods. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation, amortization, stock-based compensation expense, purchase accounting adjustments to write up acquired inventory to fair value, certain charges and expenses related to acquisitions and certain other costs and expenses not deemed reflective of the ongoing business operations of the Company. Management of the Company uses non-GAAP information internally in planning, forecasting and evaluating the Company's results of operations in the current period and in comparing it to prior periods. The Company also uses these non-GAAP measures in evaluating management performance for compensation purposes. The Company believes that this information also provides investors better insight in evaluating the Company's earnings performance from core operations and provides consistency in financial reporting. The measure, "Non-GAAP gross profit” is reconciled with GAAP gross profit in the table below:       Three Months Ended Nine Months Ended   September 29, 2007   September 30, 2006 September 29, 2007   September 30, 2006   GAAP gross profit $ 74,283 $ 67,865 $ 214,028 $ 182,332 Purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company         -         2,442         2,851         5,565 Non-GAAP gross profit (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company)         $         74,283         $         70,307         $         216,879         $         187,897 The measure, "Non-GAAP operating income” is reconciled with GAAP operating income in the table below:       Three Months Ended Nine Months Ended   September 29, 2007   September 30, 2006 September 29, 2007   September 30, 2006   GAAP operating income $ 18,266 $ 14,302 $ 44,790 $ 36,852 Purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company       2,578       3,800       10,342       8,534 Non-GAAP operating income (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company)         $ 20,844         $ 18,102         $ 55,132         $ 45,386 The measure, "Non-GAAP net income” is reconciled with GAAP net income in the table below:       Three Months Ended Nine Months Ended   September 29, 2007   September 30, 2006 September 29, 2007   September 30, 2006   GAAP net income $ 6,715 $ 4,359 $ 16,111 $ 11,632 Purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company, net of tax         1,511         2,281         6,185         6,602 Non-GAAP net income (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company)         $         8,226         $         6,640         $         22,296         $         18,234 The measure, "Non-GAAP diluted net income per share” is reconciled with GAAP net income in the table below:       Three Months Ended Nine Months Ended   September 29, 2007   September 30, 2006 September 29, 2007   September 30, 2006   GAAP diluted net income per share $ 0.28 $ 0.18 $ 0.67 $ 0.50 Purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company, net per share       0.06       0.10       0.26       0.28 Non-GAAP diluted net income per share (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions, and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company)         $ 0.34         $ 0.28         $ 0.93         $ 0.78 The measure, "Adjusted EBITDA” is reconciled with GAAP net income in the table below:       Three Months Ended Nine Months Ended   September 29, 2007   September 30, 2006 September 29, 2007   September 30, 2006   GAAP net income $ 6,715 $ 4,359 $ 16,111 $ 11,632 Plus: Interest expense, net of interest income 5,321 6,284 16,932 15,684 Provision for income taxes 6,552 4,098 12,974 9,790 Depreciation and amortization 7,631 7,395 22,595 18,645 Stock-based compensation expense 2,997 2,685 8,049 6,793 Purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company       2,578       3,800       10,342       8,625 Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company)         $ 31,794         $ 28,621         $ 87,003         $ 71,169